Hematologic Oncology

While debt from medical school loans is inevitable for most oncology and hematology fellows, there are strategies they can consider to lessen that burden.

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101

Study finds that peripheral blood stem cell (PBSC) transplants increase the incidence of graft-versus-host disease (GVHD).

Dr. James Kochenderfer from the National Cancer Institute Discusses the B-cell Antigen CD19

Dr. Tatyana Feldman from John Theurer Cancer Center Discusses the Difficulties of Rare Lymphomas

Andre Goy, MD, MS, treats lymphoma patients at New Jersey's largest cancer center, Goy, 54, is also a translational researcher widely known for his work showing the first-ever evidence of activity of bortezomib.

This month's collection of trials in progress highlights trials presented at the 2011 American Society of Clinical Oncology Meeting.

Newly-diagnosed asymptomatic follicular lymphoma patients with low tumor burden can have their initial treatment delayed.

Dr. Volker Diehl from the University of Cologne Discusses Brentuximab Vedotin

Erythropoietin-stimulating agents (ESAs), once considered miracle drugs that enjoyed widespread use for cancer-related anemia, fell into disfavor in 2007.

The availability of effective novel agents for the treatment of multiple myeloma - including thalidomide, lenalidomide, and bortezomib - has validated the concept of maintenance therapy in myeloma patients.

The FDA granted orphan drug approval to Erwinaze (asparaginase Erwinia chrysanthemi) to treat acute lymphoblastic leukemia (ALL).

Dr. James Berenson from the Institute for Myeloma & Bone Cancer Research Discusses the Carfilzomib Toxicity Profile

The FDA approved ruxolitinib (Jakafi) as the first drug to specifically treat patients with myelofibrosis, a bone marrow disease.

Outcomes in the treatment of acute lymphoblastic leukemia (ALL) differ in children and adults, with pediatric patients (including adolescents and young adults) having much higher cure rates than adults.

William I. Bensinger, MD, tackles the complex subject of the role of hematopoietic stem cell transplantation (HSCT), including when to transplant and whether to use allogeneic versus autologous transplant.

Current treatments revolutionized multiple myeloma but combinations and novel approaches in development promise to make even greater strides in treating this disease.

Dr. Volker Diehl from the University of Cologne, Germany, Compares US and EU Hodgkin Lymphoma Staging

Dr. James Berenson from the Institute for Myeloma and Bone Cancer Research Discusses the Proteasome Inhibitor Carfilzomib

Dr. Volker Diehl from the University of Cologne, Germany on the Unique Nature of Hodgkin's Lymphoma

It’s no surprise that you acquire significant debt during your medical training. Here are some ways to get those loans paid off.

Burnout is a recurring problem for overworked oncologists and hematologists. This article includes ideas to keep you healthy, engaged, and empathic.

Ideally, all patients should receive the same oncology care, regardless of their ability to pay. The reality is often different, as this fellow can attest.

Obtaining a high-quality bone marrow aspirate and biopsy is very important for the patient—and for you. Following these general guidelines will help you do this successfully.